News

Data from the CLVer trial provide insight into the effects of verapamil use on beta cell function among a cohort of children and adolescents with newly diagnosed type 1 diabetes.

A nearly two-fold increase or decrease in liver stiffness would be required to confidently represent a change in the underlying fibrosis.

There were few or no studies investigating education and training, personal protective equipment or monitoring, and evaluation of interventions.

Our March 2023 cardiology month in review features top headlines from ACC.23, an approval for children with HoFH, and a feature celebrating the 10-year anniversary of the first SGLT2 inhibitor approval.

Data suggest confirmatory trials conducted for drugs granted accelerated approval by the FDA have taken a median 3.5 years to complete since 2012.

In the latest Lungcast, a pair of experts considered the marriage of low-dose CT scanning and machine learning to optimize lung disease interception.

The new recommendations buck against the organization's prior guidance, noting the variability of reported race and ethnicity that applies to clinical assessment.

Soumya Chakravarty, MD, PhD, discussed the results of the DISCOVER-1 and DISCOVER-2 studies that evaluated the long-term efficacy of guselkumab for the treatment of adult patients with active psoriatic arthritis.

Investigators found girls with depression and anxiety responded especially well to melatonin treatment, suggesting the potential of sleep interventions in reducing the risk of self-harm.

Our March 2023 endocrine month in review highlights the top news and headlines in endocrinology from the past month, including reductions in insulin list prices, regulatory decisions, and more!

There was an 88.12% cure rate in the intention-to-treat analysis.

New trial results suggest the overall DONFL score was similar between a temporal inverted ILM flap technique and conventional ILM peeling in macular hole surgery.

The collaboration, titled the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), is the first public-private partnership designed to advance lupus discoveries and highlight patient perspective in drug development.

Digital Cognitive Behavior Therapy for Insomnia (CBT-I) is equally effective in treating insomnia in individuals with or without co-occurring chronic fatigue, according to a recent study.

A systematic review and meta-analysis suggested the relative risk per Gy increased for all cardiovascular disease and for the four major subtypes of cardiovascular disease.

Patients with dystrophic epidermolysis bullosa face near-constant pain and discomfort. While there are several measures clinicians have to help them, a curative treatment remains elusive.

A cross-sectional, case-controlled cohort study evaluated the cardiorespiratory and neuromuscular fitness of Finnish patients with JIA and healthy controls.

Our latest podcast offering is an in-depth dive into ophthalmology hosted by Dr. Sheth, featuring conversations with experts on the latest research, conference news, and daily practice.

New data demonstrate a concerning link between particulate matter ≤2.5 μm exposure and the risk of prolonged symptoms of COVID-19 in young adults.

In another segment of her interview, Armstrong explained the implications of her team’s findings for the newly-developed TYK2 inhibitor for plaque psoriasis, as well as its safety profile data.

There was also significantly greater reductions in anxiety, Afghan-cultural distress symptoms, and psychiatric difficulties compared to the treatment as usual group.

The first study to examine joint effects of physical activity and sleep duration on mortality risk using accelerometry, results indicate increase activity could negate the effects of short or long sleep duration on cardiovascular and all-cause mortality.

Treatment with secukinumab was safe and effective for patients with ankylosing spondylitis and psoriatic arthritis, with significant reductions in disease activity scores observed through 52 weeks.

New data discussed by Armstrong in this interview shows promising results for the once-per-day TYK2 inhibitor treatment known as TAK-279 for plaque psoriasis.

At the 6 month follow-up visit, all participants had stable folic acid levels without macrocytic anemia and the monthly questionnaires showed no increase in symptoms or adverse events reported.

Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.

Three-year results from the CIRTED trial reported no clear evidence of benefit for the addition of azathioprine to high dose oral steroid in individuals with moderate to severe TED.

During his latest interview, Lal further explored the topic of recessive dystrophic epidermolysis bullosa and his experiences helping patients with the rare condition.

An entire population gradually loses their vision, impeding everyday activities like driving in the dark, while investigators explore gene therapies in a race against the clock.

An analysis of data from the St. Jude Lifetime Cohort Study provides new insight into the risk of long-term diastolic dysfunction associated with cardiotoxic cancer therapies in adult survivors of childhood cancer.